RIMAG GROUP (02522) announced that on April 26, 2026, the company, the buyer RIMAG Medical Imaging (Hong Kong) Limited, Seller 1 Sun Seeds Management Co., Limited, and Target Company 1 Hong Kong Sun Seeds Management Co., Limited entered into Share Purchase Agreement 1. Under this agreement, the buyer intends to acquire Target Equity 1 (100% equity interest in Target Company 1) for a total consideration of HK$185 million. Separately, the company, the buyer, Seller 2 Wingon Value No. 4 Limited Partnership Fund, and Target Company 2 Wingon Medical Technology Co., Limited entered into Share Purchase Agreement 2. This agreement stipulates the buyer's intention to acquire Target Equity 2 (100% equity interest in Target Company 2) for a total consideration of HK$168 million. The consideration will be settled through the issuance of consideration shares by the company to the sellers.
Following the completion of Share Purchase Agreement 1, the group will hold an interest in 100% of Target Company 1's equity. Target Company 1 will become an indirect wholly-owned subsidiary of the company, and its financial results will be consolidated into the group's accounts. As of the date of this announcement, Target Company 1 has no substantive business operations, and its sole asset is an 8.8275% equity stake in Yinghe Yimai.
Upon completion of Share Purchase Agreement 2, the group will hold an interest in 100% of Target Company 2's equity. Target Company 2 will become an indirect wholly-owned subsidiary, and its financial results will also be consolidated. Target Company 2 currently has no substantive business operations, and its sole asset is an 8.0000% equity stake in Yinghe Yimai.
This acquisition represents a critical step for the group, transitioning from project incubation to strategic heavy investment. It is a core initiative to perfect the trinity strategic layout of "data-model-scenario" and solidly strengthen the underlying AI technological capabilities. The move is pivotal for RIMAG GROUP to realize its global digital-intelligent imaging+ ecosystem layout and strategic value upgrade, fully aligning with the group's long-term development plan to deeply cultivate the medical imaging field.
The further increase in the stake in Yinghe Yimai fully demonstrates the group's strong confidence in Yinghe Yimai's long-term future development and shows high strategic alignment with the overall transformation and upgrade needs of RIMAG GROUP's digital-intelligent imaging+ strategy. By deepening cooperation through capital ties, both parties are upgrading to a symbiotic development model. The group leverages its operational advantages from a nationwide network of imaging centers to accumulate vast amounts of high-quality clinical data and application scenarios. Yinghe Yimai, with cutting-edge technological innovation as its core engine, continuously iterates large model and AI agent capabilities. This creates a bidirectional, closed-loop cycle where data drives technology and technology empowers scenarios, establishing a sustainable, synergistic development system. By deeply integrating their respective core strengths, the two parties will work symbiotically to build core barriers in medical imaging AI that are difficult for the industry to replicate.
Strategically, this acquisition will bring multiple value enhancements for the group. From an industrial chain perspective, it leverages Yinghe Yimai's top-tier AI technology advantages to address technological gaps, complete the business layout, and accelerate the upgrade towards data-driven intelligent medical services, thereby strengthening core competitiveness. From a service perspective, the implementation of advanced AI technology will effectively enhance diagnostic accuracy and operational efficiency for various imaging centers and partner medical institutions, better meeting clinical diagnosis and treatment needs. Regarding industry positioning, it will help the group seize development opportunities in the imaging AI sector, consolidate first-mover advantages, drive steady business growth, and solidify the group's leading position in the domestic medical imaging AI industry.
Comments